France· FR:66833683
NINLARO 3 mg, gélule
A medicinal product containing citrate d'ixazomib, registered in France by TAKEDA PHARMA (DANEMARK), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CITRATE D'IXAZOMIB
- Manufacturer
- TAKEDA PHARMA (DANEMARK)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300777193 plaquette(s) PVC aluminium de 1 gélule(s)EUR 3.36
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Citrate d'ixazomib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomIxazomib 3mg capsulesTakeda UK Ltd
- United StatesNINLAROTakeda Pharmaceuticals America, Inc.
- SwitzerlandNinlaro 3.0 mg, HartkapselnTakeda Pharma AG
- CzechiaNINLAROTakeda Pharma A/S, Vallensbaek Strand
- SpainNINLARO 3 MG CAPSULAS DURASTakeda Pharma A/S
- FinlandNINLAROTakeda Pharma A/S
- BelgiumNinlaro 3 mgTakeda Pharma
- IcelandNinlaroTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ninlaro
- Liechtenstein · Ninlaro
- Norway · Ninlaro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/73201efc-219e-4b11-b13e-7d5cbdedc41a GET /v1/drugs/73201efc-219e-4b11-b13e-7d5cbdedc41a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66833683",
"date_amm": "2016-11-21",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/16/1094",
"substance": "CITRATE D'IXAZOMIB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about citrate d'ixazomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.